{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:51:56Z","timestamp":1781531516812,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pompe disease is a rare glycogen storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to glycogen deposition in multiple tissues. Infantile-onset Pompe disease (IOPD) patients present within the first year of life with profound hypotonia and hypertrophic cardiomyopathy. Treatment with enzyme replacement therapy (ERT) has significantly improved survival for this otherwise lethal disorder. This study aims to describe the clinical and molecular spectrum of Malaysian IOPD patients, and to analyze their long term treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seventeen patients diagnosed with IOPD between 2000 and 2020 were included in this retrospective cohort study. Clinical and biochemical data were collated and analyzed using descriptive statistics. GAA enzyme levels were performed on dried blood spots. Molecular analysis of the\n                      <jats:italic>GAA<\/jats:italic>\n                      gene was performed by polymerase chain reaction and Sanger sequencing. Structural modelling was used to predict the effect of the novel mutations on enzyme structure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our cohort had a median age of presentation of 3\u00a0months and median age of diagnosis of 6\u00a0months. Presenting features were hypertrophic cardiomyopathy (100%), respiratory insufficiency (94%), hypotonia (88%), failure to thrive (82%), feeding difficulties (76%), and hepatomegaly (76%). Fourteen different mutations in the GAA gene were identified, with three novel mutations, c.1552-14_1552-1del, exons 2\u20133 deletion and exons 6\u201310 deletion. The most common mutation identified was c.1935C\u2009&gt;\u2009A p.(D645E), with an allele frequency of 33%. Sixteen patients received ERT at the median age of 7\u00a0months. Overall survival was 29%. Mean age of death was 17.5\u00a0months. Our longest surviving patient has atypical IOPD and is currently 20\u00a0years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to analyze the genotype and phenotype of Malaysian IOPD patients, and has identified the c.1935C\u2009&gt;\u2009A p.(D645E) as the most common mutation. The three novel mutations reported in this study expands the mutation spectrum for IOPD. Our low survival rate underscores the importance of early diagnosis and treatment in achieving better treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02848-6","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T10:03:47Z","timestamp":1691143427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-9374","authenticated-orcid":false,"given":"Mei-Yan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julaina Abdul","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusnita","family":"Yakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Aishah Abdul","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie Zuraida","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Khairul Nizam Mohd","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huey-Yin","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Bein","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeya Bawani","family":"Sivabalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lock-Hock","family":"Ngu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"1","key":"2848_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj0860011","volume":"86","author":"HERS","year":"1963","unstructured":"HERS. alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe\u2019s disease). Biochem J. 1963;86(1):11\u20136.","journal-title":"Biochem J"},{"key":"2848_CR2","first-page":"3389","volume-title":"The metabolic and molecular bases of inherited disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R, Reuser AJJ, et al. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Beaudet A, Scriver C, Sly W, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2001. p. 3389\u2013420."},{"issue":"2","key":"2848_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332\u201340.","journal-title":"Pediatrics"},{"issue":"5","key":"2848_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671\u20136.","journal-title":"J Pediatr"},{"key":"2848_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1067\/mpd.2000.107112","volume":"137","author":"AE Slonim","year":"2000","unstructured":"Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr. 2000;137:283\u20135.","journal-title":"J Pediatr"},{"issue":"2","key":"2848_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109.","journal-title":"Neurology"},{"issue":"2","key":"2848_CR7","first-page":"132","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med. 2001;3(2):132\u20138.","journal-title":"Genet Med"},{"key":"2848_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","volume":"169","author":"CF Yang","year":"2016","unstructured":"Yang CF, Chen CY, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016;169:174-180.e1.","journal-title":"J Pediatr"},{"key":"2848_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/8904_2014_392","volume":"20","author":"A Hahn","year":"2015","unstructured":"Hahn A, Praetorius S, Karabul N, et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65\u201375.","journal-title":"JIMD Rep"},{"key":"2848_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","volume":"39","author":"A Broomfield","year":"2016","unstructured":"Broomfield A, Fletcher J, Davison J, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39:261\u201371.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2848_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","volume":"38","author":"CM van Gelder","year":"2015","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305\u201314.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2848_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2848_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","volume":"160C","author":"DS Bali","year":"2012","unstructured":"Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40\u20139.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2848_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/humu.24148","volume":"42","author":"DOS Faria","year":"2021","unstructured":"Faria DOS, Groen SLM, Hoogeveen-Westerveld M, et al. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021;42:119\u201334.","journal-title":"Hum Mutat"},{"issue":"13","key":"2848_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.21037\/atm.2019.04.13","volume":"7","author":"P Peruzzo","year":"2019","unstructured":"Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019;7(13):278.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2848_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u201339.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2848_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.echo.2009.03.003","volume":"22","author":"PR Khoury","year":"2009","unstructured":"Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr. 2009;22(6):709\u201314.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1,2","key":"2848_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","volume":"347","author":"NA Chamoles","year":"2004","unstructured":"Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta. 2004;347(1,2):97\u2013102.","journal-title":"Clin Chim Acta"},{"issue":"9","key":"2848_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/pro.5560020916","volume":"2","author":"C Colovos","year":"1993","unstructured":"Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511\u20139.","journal-title":"Protein Sci"},{"key":"2848_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK\u2014a program to check the stereochemical quality of protein structures. J Appl Cryst. 1993;26:283\u201391.","journal-title":"J Appl Cryst"},{"issue":"Web Server issu","key":"2848_CR21","doi-asserted-by":"publisher","first-page":"W407","DOI":"10.1093\/nar\/gkm290","volume":"35","author":"M Wiederstein","year":"2007","unstructured":"Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server issue):W407\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"2848_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701\u201318.","journal-title":"J Comput Chem"},{"key":"2848_CR23","volume-title":"The PyMOL molecular graphics system","author":"WL DeLano","year":"2002","unstructured":"DeLano WL. The PyMOL molecular graphics system. San Carlos: DeLano Scientifc; 2002."},{"issue":"4","key":"2848_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41436-018-0270-7","volume":"21","author":"ZB Kazi","year":"2019","unstructured":"Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, et al. An immune tolerance approach using transient low-dose methotrexate in the ERT-na\u00efve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med. 2019;21(4):887\u201395.","journal-title":"Genet Med"},{"issue":"1","key":"2848_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.gene.2013.10.066","volume":"535","author":"L Fu","year":"2014","unstructured":"Fu L, Qiu W, Yu Y, Guo Y, Zhao P, Zhang X, et al. Clinical and molecular genetic study of infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations. Gene. 2014;535(1):53\u20139.","journal-title":"Gene"},{"key":"2848_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A","volume":"13","author":"TM Ko","year":"1999","unstructured":"Ko TM, Hwu WL, Lin YW, Tseng LH, Hwa HL, Wang TR, et al. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat. 1999;13:380\u20134.","journal-title":"Hum Mutat"},{"key":"2848_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12881-019-0878-8","volume":"20","author":"L Ngiwsara","year":"2019","unstructured":"Ngiwsara L, Wattanasirichaigoon D, Tim-Aroon T, et al. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand. BMC Med Genet. 2019;20:156.","journal-title":"BMC Med Genet"},{"key":"2848_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12881-014-0141-2","volume":"15","author":"X Liu","year":"2014","unstructured":"Liu X, Wang Z, Jin W, et al. Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation. BMC Med Genet. 2014;15:141.","journal-title":"BMC Med Genet"},{"issue":"6","key":"2848_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/gtmb.2016.0424","volume":"21","author":"X Chen","year":"2017","unstructured":"Chen X, Liu T, Huang M, Wu J, Zhu J, Guo Y, et al. Clinical and molecular characterization of infantile-onset Pompe disease in mainland Chinese patients: identification of two common mutations. Genet Test Mol Biomark. 2017;21(6):391\u20136.","journal-title":"Genet Test Mol Biomark"},{"key":"2848_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ymgme.2007.07.006","volume":"92","author":"ME McCready","year":"2007","unstructured":"McCready ME, Carson NL, Chakraborty P, Clarke JT, Callahan JW, Skomorowski MA, Chan AK, Bamforth F, Casey R, Rupar CA, Geraghty MT. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab. 2007;92:325\u201335.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2848_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1086\/339691","volume":"70","author":"ML Huie","year":"2002","unstructured":"Huie ML, Anyane-Yeboa K, Guzman E, Hirschhorn R. Homozygosity for multiple contiguous single-nucleotide polymorphisms as an indicator of large heterozygous deletions: identification of a novel heterozygous 8-kb intragenic deletion (IVS7-19 to IVS15-17) in a patient with glycogen storage disease type II. Am J Hum Genet. 2002;70(4):1054\u20137.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"2848_CR32","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","volume":"40","author":"AJJ Reuser","year":"2019","unstructured":"Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J Jr, Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat. 2019;40(11):2146\u201364.","journal-title":"Hum Mutat"},{"issue":"8","key":"2848_CR33","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1074\/jbc.M404008200","volume":"280","author":"RJ Moreland","year":"2005","unstructured":"Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem. 2005;280(8):6780\u201391.","journal-title":"J Biol Chem"},{"key":"2848_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","volume":"8","author":"V Roig-Zamboni","year":"2017","unstructured":"Roig-Zamboni V, Cobucci-Ponzano B, Iacono R, et al. Structure of human lysosomal acid \u03b1-glucosidase\u2013a guide for the treatment of Pompe disease. Nat Commun. 2017;8:1111.","journal-title":"Nat Commun"},{"issue":"14","key":"2848_CR35","first-page":"3","volume":"31","author":"Y Fukuhara","year":"2017","unstructured":"Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;31(14):3\u20139.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2848_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","volume":"13","author":"R Parini","year":"2018","unstructured":"Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet J Rare Dis. 2018;13(1):32.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"2848_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Sch\u00e4nzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7(13):283.","journal-title":"Ann Transl Med"},{"issue":"2","key":"2848_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","volume":"123","author":"PT McIntosh","year":"2018","unstructured":"McIntosh PT, Hobson-Webb LD, Kazi ZB, et al. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab. 2018;123(2):85\u201391.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2848_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","volume":"166","author":"YH Chien","year":"2015","unstructured":"Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985-991.e2.","journal-title":"J Pediatr"},{"issue":"6","key":"2848_CR40","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dmcn.13740","volume":"60","author":"BJ Ebbink","year":"2018","unstructured":"Ebbink BJ, Poelman E, Aarsen FK, Plug I, R\u00e9gal L, Muentjes C, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018;60(6):579\u201386.","journal-title":"Dev Med Child Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02848-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:33:06Z","timestamp":1700375586000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02848-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02848-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1721748\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"3 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by the Malaysian Medical Research and Ethics Committee prior to study initiation. (NMRR-21-652-58205).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}